Summary
BeiGene, Ltd. (ONC) reported its first quarter 2017 financial results, showcasing a significant increase in research and development (R&D) expenses as the company continued to advance its clinical-stage oncology pipeline. Total operating expenses more than doubled year-over-year, driven primarily by R&D investments in key drug candidates like BGB-3111, BGB-A317, BGB-290, and BGB-283. The company reported a net loss of $50.6 million, widening from $22.0 million in the prior year’s quarter, reflecting its ongoing commitment to drug development. Financially, BeiGene ended the quarter with $327.5 million in cash, cash equivalents, and short-term investments, indicating a solid liquidity position to fund operations for at least the next twelve months, following successful IPO and follow-on offerings in 2016. Revenue from collaboration agreements was nil, down from $0.7 million in Q1 2016, as earlier collaborations with Merck KGaA concluded. The company continues to focus on building its manufacturing capabilities and expanding its global operations, with significant capital expenditures noted for its Suzhou and Guangzhou facilities.
Financial Highlights
45 data points| Revenue | $0 |
| R&D Expenses | $42.77M |
| SG&A Expenses | $8.77M |
| Operating Expenses | $51.54M |
| Operating Income | -$51.54M |
| Net Income | -$50.62M |
| EPS (Basic) | $-0.10 |
| EPS (Diluted) | $-0.10 |
| Shares Outstanding (Basic) | 516.44M |
Key Highlights
- 1Net loss widened to $50.6 million in Q1 2017 from $22.0 million in Q1 2016, driven by increased operating expenses.
- 2Research and Development (R&D) expenses increased significantly to $42.8 million from $17.9 million, reflecting investment in clinical pipeline advancement.
- 3Total revenue was nil for Q1 2017, a decrease from $0.7 million in Q1 2016, due to the conclusion of collaboration revenue recognition.
- 4Cash, cash equivalents, and short-term investments totaled $327.5 million as of March 31, 2017, providing a strong liquidity position.
- 5The company's cash burn from operating activities was $35.7 million in Q1 2017.
- 6Property and equipment, net, increased to $30.7 million, reflecting investments in manufacturing and laboratory facilities.
- 7Share-based compensation expense increased to $6.0 million from $2.6 million, primarily due to increased headcount in R&D and G&A.